Gluconorm-G Plus 3 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 850 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and improving peripheral insulin sensitivity, contributing to decreased blood glucose levels. This combination provides complementary mechanisms of action, offering effective glycemic management in patients inadequately controlled by diet and exercise alone or monotherapy. Gluconorm-G Plus 3 Tablet PR is designed for prolonged release, ensuring sustained plasma concentrations and improved patient compliance. It is recommended to be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is essential during therapy. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and rare lactic acidosis. This formulation should be used as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and exercise, under the supervision of a healthcare professional.